NCT06657430 A Study on the Preference of Risperidone Dosage Forms
| NCT ID | NCT06657430 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Mental Health Center |
| Condition | Schizophrenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-09-19 |
| Primary Completion | 2025-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-09-19 with a primary completion date of 2025-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aimed to understand patients' needs and preferences for antipsychotic dosage forms.
Eligibility Criteria
Inclusion Criteria: * Patients with schizophrenia, bipolar disorder, autism spectrum disorder, mental retardation or their primary caregivers who voluntarily participate in the study. Exclusion Criteria: * Have difficulty reading and understanding Chinese or refuse to participate in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06657430 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06657430 currently recruiting?
Yes, NCT06657430 is actively recruiting participants. Contact the research team at lan-luo@foxmail.com for enrollment information.
Where is the NCT06657430 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06657430 clinical trial?
NCT06657430 is sponsored by Shanghai Mental Health Center. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.